1 / 7

ICARE Member Reports

ICARE Member Reports. NIH Counter measures A gainst C hemical T hreats ( CounterACT ) Program To develop FDA-approved therapeutics and diagnostic technologies that will reduced mortality and morbidity during and after chemical emergency events. Chemical Nerve Agents. PHYSIOLOGICAL

syshe
Download Presentation

ICARE Member Reports

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ICARE Member Reports • NIH Countermeasures Against Chemical Threats (CounterACT) Program • To develop FDA-approved therapeutics and diagnostic technologies that will reduced mortality and morbidity during and after chemical emergency events

  2. Chemical Nerve Agents PHYSIOLOGICAL AND METABOLIC EFFECTS Seizure-Pathology Model NEURONAL DAMAGE ACTIVATION OF MUSCARINIC RECEPTORS EPILEPTIFORM ACTIVITY NERVE AGENT INHIBITION OF AChE RISE IN ACh INTRACELLULAR ACCUMULATION OF Ca++ ACTIVATION OF GLUTAMATE RECEPTORS • Therapeutic Approaches: • Anticholinergics • AChE Reactivators • Anticonvulsants • Neuroprotectants • Single Antidote

  3. LD50 of VX

  4. ICARE Member Reports: CounterACT • Major topics of interest in epilepsy research • Anticonvulsant and Neuroprotectant Research & Development • Emergency Medical Intervention (Diagnosis & Treatment of Seizures) • Treatment of Refractory and Recurring Seizures

  5. ICARE Member Reports: CounterACT • Types of research support or other activities • Basic and translational research portfolio • Co-funding of RAMPART: a clinical trial on the pre-hospital use of IM midazolam in an autoinjector • Support for NINDS Anticonvulsant Screening Program (CounterACT Tract) • Development of a portable, field-deployable EEG device (3 prototypes being tested)

  6. ICARE Member Reports: CounterACT • Resources available for shared use or other opportunities for collaboration • Anticonvulsant Screening Program – U. Utah • CounterACT Preclinical Development Facility (SRI Int. – Menlo Park, CA) • US Army MRICD – Aberdeen, MD (Screening w/ nerve agents) • Battelle Labs - Columbus, OH (GLP Screening w/ nerve agents)

  7. ICARE Member Reports: CounterACT • Priorities for future activities • Translating basic discoveries made during first 5 years to clinic • Next generation anticonvulsants and neuroprotectants • Cast a wide net to capture potential lead compounds • Repositioning FDA-approved drugs

More Related